These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33725402)

  • 1. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.
    Wada Y; Shimada M; Yamamura K; Toshima T; Banwait JK; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Hepatology; 2021 Sep; 74(3):1371-1383. PubMed ID: 33725402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma.
    Sulpice L; Rayar M; Turlin B; Boucher E; Bellaud P; Desille M; Meunier B; Clément B; Boudjema K; Coulouarn C
    J Surg Res; 2014 Nov; 192(1):117-23. PubMed ID: 24909871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma.
    Ruan J; Xu S; Chen R; Qu W; Li Q; Ye C; Wu W; Jiang Q; Yan F; Shen E; Chu Q; Jia Y; Zhang X; Fu W; Chen J; Timko MP; Zhao P; Fan L; Shen Y
    Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36259363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma.
    Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Br J Cancer; 2022 May; 126(8):1196-1204. PubMed ID: 35079106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
    Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
    Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
    Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
    Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
    Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma.
    Tan J; Shu M; Liao J; Liang R; Liu S; Kuang M; Peng S; Xiao H; Zhou Q
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12365-12377. PubMed ID: 37436513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
    Zhou SL; Xin HY; Sun RQ; Zhou ZJ; Hu ZQ; Luo CB; Wang PC; Li J; Fan J; Zhou J
    JAMA Surg; 2022 Jan; 157(1):59-65. PubMed ID: 34730772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
    Yu WL; Yu G; Dong H; Chen K; Xie J; Yu H; Ji Y; Yang GS; Li AJ; Cong WM; Jin GZ
    J Gastroenterol; 2020 Dec; 55(12):1171-1182. PubMed ID: 33089343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterisation of six human biliary tract cancer cell lines.
    Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
    Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
    Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
    Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
    Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
    Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma.
    Xie X; Wang Y; Zhang S; Li J; Yu Z; Ding X; Ye L; Gong P; Zhu Q; Li J; Chen Z; Yao X; Du Z; Zeng Q; Chen H; Yang Z; Chen G
    Aging (Albany NY); 2021 Jan; 13(2):2959-2981. PubMed ID: 33472169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis.
    Zhang MY; Li SH; Huang GL; Lin GH; Shuang ZY; Lao XM; Xu L; Lin XJ; Wang HY; Li SP
    BMC Cancer; 2015 Feb; 15():64. PubMed ID: 25880914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated mRNA-lncRNA signature for overall survival prediction in cholangiocarcinoma.
    Xu D; Wei L; Zeng L; Mukiibi R; Xin H; Zhang F
    Medicine (Baltimore); 2023 Sep; 102(39):e35348. PubMed ID: 37773863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
    Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
    J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.
    Nishiwada S; Cui Y; Sho M; Jun E; Akahori T; Nakamura K; Sonohara F; Yamada S; Fujii T; Han IW; Tsai S; Kodera Y; Park JO; Von Hoff D; Kim SC; Li W; Goel A
    Ann Surg; 2022 Dec; 276(6):e876-e885. PubMed ID: 34132691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.